Signs and Artifacts in Amyloid PET
Abstract
With the advent of amyloid PET, the radiologist now plays a pivotal role in diagnosis of Alzheimer disease and therefore must have an algorithmic approach to scan interpretation as well as knowledge of the common signs and artifacts.
Establishing a diagnosis of Alzheimer dementia can be challenging, particularly early in the course of the disease. However, with disease-modifying therapies on the horizon, it is becoming increasingly important to achieve the correct diagnosis as soon as possible. In challenging presentations of dementia, such as patients with clinically atypical features or early-age onset of mild cognitive impairment, amyloid PET is a valuable tool in determining the diagnosis of Alzheimer dementia. Furthermore, preliminary data show that amyloid PET findings alter clinical management in patients who meet the appropriate use criteria. There are currently three U.S. Food and Drug Administration (FDA)–approved fluorine 18 (18F)–labeled radiopharmaceuticals that allow in vivo detection of cerebral amyloid deposition, which is a hallmark pathologic feature of Alzheimer dementia. Knowledge of the common imaging features among these three 18F-labeled radiopharmaceuticals in the normal and abnormal brain will enable the radiologist to more accurately interpret amyloid PET studies. As in other subspecialties of radiology, imaging signs in amyloid PET are helpful to distinguish if a region is normal or abnormal. This article reviews appropriate use criteria for amyloid PET, introduces the properties of the radiopharmaceuticals, explains the algorithmic approach to interpretation with examples of normal and abnormal amyloid PET scans with MRI correlation, and provides an atlas of regional amyloid PET signs and common artifacts.
©RSNA, 2018
References
- 1. ;
Alzheimer Disease International . The worldwide economic impact of dementia 2010. Alzheimers Dement 2013;9(1):1–11.e3. - 2. . Aβ-amyloid and tau imaging in dementia. Semin Nucl Med 2017;47(1):75–88.
- 3. . Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66(12):1469–1475.
- 4. . The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016;537(7618):50–56.
- 5. . Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial. Alzheimer Dis Assoc Disord 2016;30(1):1–7.
- 6. . Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 2004;55(3):306–319.
- 7. . Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer’s disease brain but not in transgenic mouse brain. J Neurosci 2005;25(46):10598–10606.
- 8. . Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol (Berl) 2012;124(6):823–831.
- 9. . A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002;12(3):295–298.
- 10. . [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67(3):446–452.
- 11. . Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013;9(5 suppl):S72–S83.
- 12. . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67(1):122–131.
- 13. . SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med 2016;57(8):1316–1322.
- 14. . Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68(20):1718–1725.
- 15. . Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther 2011;3(6):31.
- 16. . Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 2011;32(suppl 1):S20–S36.
- 17. . Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement 2013;9(1):e-1–e-16.
- 18. . Highlights of prescribing information. https://www3.gehealthcare.com/∼/media/documents/us-global/products/nuclear-imaging-agents_non-gatekeeper/clinical product info/vizamyl/gehealthcare-vizamyl-prescribing-information.pdf2017. Published February 2012. Accessed January 2018.
- 19. . Highlights of prescribing information Amyvid (florbetapir F 18 injection). https://pi.lilly.com/us/amyvid-uspi.pdf. Revised December 2013. Accessed January 2018.
- 20. . Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf. Revised March 2014. Accessed January 2018.
- 21. . In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010;51(6):913–920.
- 22. . 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68(3):319–329.
- 23. . Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7(2):129–135.
- 24. . Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305(3):275–283.
- 25. . Florbetapir-PET imaging and postmortem beta-amyloid pathology. JAMA 2011;305(18):1857; author reply 1857–1858.
- 26. . Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer’s disease. Alzheimers Dement (Amst) 2017;9:25–34.
- 27. . The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991;41(4):479–486.
Article History
Received: Apr 20 2018Revision requested: May 25 2018
Revision received: June 29 2018
Accepted: July 2 2018
Published online: Nov 13 2018
Published in print: Nov 2018